UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 31, 2003
Access Pharmaceuticals, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-9314 83-0221517
- ------------------------ ------------------------ ---------------------
(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)
2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207
- ----------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (214) 905-5100
Not applicable
-------------------------------------------------------------
(Former name or former address; if changed since last report)
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
- ----------------------------------------------------------------------------
(c) Exhibits
Exhibit
Number Description
- ------- -----------
99.1 Press Release dated March 31, 2003 - "Access
Pharmaceuticals Reports Fourth Quarter and Year-End Results"
Item 12. Results of Operations and Financial Condition
- --------------------------------------------------------
On March 31, 2003 the registrant issued a Press Release relating to its
2002 fourth quarter and year end results. The Press Release is attached
as an Exhibit to this Report on Form 8-K.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Access Pharmaceuticals, Inc.
(Registrant)
By: /s/ Kerry P. Gray
--------------------
Kerry P. Gray
President and CEO
Dated April 1, 2003
3
EXHIBIT INDEX
Exhibit
Number Description
- ------- -------------
99.1 "Access Pharmaceuticals Reports Fourth
Quarter and Year-End Results"
4